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Objectives: To assess the efficacy and safety of etoricoxib 60 mg once daily and naproxen 500 mg twice
daily over a 138-week treatment period in patients with osteoarthritis (OA).
Methods: Two 1-year randomised, double blind, parallel group two-part base studies (part I 12 weeks; part II
40 weeks), followed by an 86-week extension, in patients with OA (hip or knee) were conducted at 80 clinical
centres (19 countries). The studies had identical designs. Patients taking placebo in part I received etoricoxib
or naproxen (1:1 ratio) in part II and the extension; patients taking etoricoxib or naproxen in part I continued
to receive the same treatment throughout the entire length of the studies. Co-primary efficacy end points were
patient global assessment of disease status, and WOMAC questionnaire pain subscale and physical function
subscale (100 mm VAS). Efficacy over 138 weeks was assessed by graphical analysis. Safety was assessed
by observation of adverse experiences and laboratory and physical evaluations.
Results: 997 patients entered (615 completed) the base studies. Of these patients, 463 patients entered the
extensions. A total of 161 and 152 patients in the etoricoxib and naproxen groups, respectively, completed
138 treatment weeks. Etoricoxib and naproxen showed similar efficacy throughout the 138 weeks of
treatment. For etoricoxib and naproxen, respectively, WOMAC pain assessments were 67 and 67 mm
(baseline); 28 and 29 mm (1 year), and 34 and 33 mm (138 weeks). Results for the other efficacy end points
were similar to those seen with the WOMAC pain assessments. Both etoricoxib and naproxen were generally
well tolerated.
Conclusion: Both etoricoxib and naproxen demonstrated long-term clinical efficacy for the treatment of OA.
Etoricoxib and naproxen were generally well tolerated.
O
steoarthritis (OA) is a condition characterised by loss of
articular cartilage in synovial joints, osteophyte forma-
tion, subchondral bone change and synovitis.1 2 Patients
with OA experience symptoms such as pain, loss of physical
function and, in the advanced stages, disability.1 3 4 The goal of
treatment is to increase joint function and improve quality of
life. Non-pharmacological approaches, such as diet and
exercise, as well as the use of paracetamol for the reduction
of pain are recommended for patients with mild to moderate
OA. For patients who require greater efficacy, non-steroidal
anti-inflammatory drugs (NSAIDs) or selective cyclo-oxygenase
(COX)-2 inhibitors are often prescribed. Although many
treatments are available, selection of a therapeutic approach
for patients is often difficult and involves weighing benefits of a
particular treatment against its potential risks on an individual
basis.
Traditional, non-selective NSAIDs inhibit both isoforms of
cyclo-oxygenase: COX-1 and COX-2. These analgesic agents
have demonstrated their value in the treatment of pain from
OA, but, their use is associated with gastrointestinal (GI)
adverse experiences (AEs) such as ulcers and GI bleeding
because of their potent inhibition of the gastroprotective COX-1
isoform.5 6 Selective COX-2 inhibitors have demonstrated
comparable efficacy in chronic and acute pain, with signifi-
cantly improved GI tolerability compared with traditional
NSAIDs.7
Etoricoxib is a COX-2 selective inhibitor that has demon-
strated efficacy in patients with OA.8 The objective of the
current analysis was to assess the maintenance of efficacy and
tolerability of etoricoxib 60 mg once daily and naproxen
500 mg twice daily in patients with OA in a combined analysis
of two studies over 138 weeks of treatment. Recent studies
have suggested that COX-2 selective inhibitors are associated
with an increased risk of thrombotic cardiovascular (CV) events
in comparison with placebo.9 10 Data are also available that
suggest that traditional NSAIDs are associated with increased
CV risk.11 In this analysis, data on CV AEs were collected and
adjudicated by an external safety monitoring committee;
however, these studies were not powered or designed specifi-
cally to evaluate the CV safety profile of etoricoxib.
METHODS
Two studies, protocols 018 and 019, were conducted at 47
centres in the United States and 33 centres internationally
(United States, Europe, Canada and Australia), respectively.
The protocol and consent forms were approved by institutional
review boards or ethics review committees for each study site.
Each patient provided written informed consent before entering
the base studies and before starting the extension studies.
Patient inclusion/exclusion
Patients who entered the base studies were .40 years of age
and had clinical symptoms or a clinical diagnosis of OA of the
knee or hip, based on clinical and radiographic criteria, for
more than 6 months before the start of the studies. Patients
who entered the extension studies were required to have
Abbreviations: AEs, adverse experiences; CI, confidence interval; COX,
cyclo-oxygenase; CV, cardiovascular; GI, gastrointestinal; NSAIDs, non-
steroidal anti-inflammatory drugs; OA, osteoarthritis; PUBs, perforations,
ulcers, or bleeding events; VAS, visual analogue scale; WOMAC, Western
Ontario and McMaster Universities OA Index
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fulfilled eligibility requirements for the base studies and to have
tolerated treatment during the previous treatment period.
Patients were classified as American Rheumatism Association
functional class I, II, or III. Other than OA, the patients were in
general good health. Female patients of child-bearing potential
were instructed to use contraception and were excluded if they
were pregnant. Patients included in the studies were regular
users of either NSAIDs or paracetamol (ie, patients had used
these analgesics for at least 25 of the previous 30 days before
study enrolment). The number of paracetamol users enrolled at
each study site was limited to 20%. Recent sustained use (ie, 6
consecutive days during the month before enrolment) of H2
receptor antagonists or proton pump inhibitors was not
permitted. Proton pump inhibitors and H2 receptor antagonists
were permitted at over the counter and prescription doses, as
needed, after randomisation. Up to one-third of patients were
allowed to take low-dose aspirin((100 mg/day). Paracetamol
(325 mg tablets) was available as rescue medication; rescue
medication use was restricted (ie, it was not permitted during
the initial 2 weeks of treatment) and recorded. All other
analgesic drugs were not permitted. The following drugs were
also not permitted during the studies: warfarin, ticlopidine,
clopidogrel, anti-epileptic drugs, digoxin, rifampin, dexametha-
sone, or lithium.
Prestudy NSAID users were required to demonstrate worsen-
ing of pain (flare) after a prespecified washout period based on
the half-life of the drug. The length of the washout period was
based on the individual drug, but was at least 3 days and as
many as 15 days. They were required to meet two flare criteria:
(a) >40 mm and an increase of 15 mm compared with
screening values on question 1 of the Western Ontario and
McMaster Universities OA Index (WOMAC),12 pain while
walking on a flat surface (100 mm visual analogue scale
(VAS)) and (b) a worsening on the investigator’s global
Figure 1 Patient accounting and study design displaying part I (weeks 0–12), part II (weeks 12–52), and the extension (weeks 52–138).
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assessment of disease status by >1 point on a 0–4 point Likert
scale. At the flare visit, prestudy paracetamol users were
required to have a response on the investigator’s global
assessment of disease status as fair, poor, or very poor and
had to demonstrate reproducible disease activity compared
with the screening visit: >40 mm pain while walking on a flat
surface (WOMAC 100 mm VAS) and the patient’s global
assessment of disease status (100 mm VAS).
Study design
The initial base studies, which had replicate study designs,
randomised patients to receive placebo, etoricoxib 60 mg once
daily, or naproxen 500 mg twice daily. Each base study
consisted of a 12-week placebo and active-comparator con-
trolled period (part I) followed by a 40-week active-comparator
controlled period (part II); this was followed by an 86-week
active-comparator controlled extension period. In part I,
patients were randomly allocated (according to a computer-
generated allocation schedule) to once-daily etoricoxib 60 mg
or matching placebo or naproxen 1000 mg (500 mg twice daily,
or matching placebo twice daily) in a blinded, double-dummy
fashion. In part II and the extensions, patients took etoricoxib
60 mg (once daily) or naproxen 1000 mg (500 mg twice daily)
in a blinded, double-dummy fashion. Patients taking placebo in
part I were randomly assigned to take etoricoxib 60 mg (50%)
or naproxen 1000 mg (50%) in part II and the extensions.
Patients taking etoricoxib 60 mg or naproxen 1000 mg in part I
continued to follow the same regimen throughout the base
study and extension.
Study visits occurred at weeks 2, 4, 8, 12, 19, 26, 33, 39, 45,
and 52 during the base studies. During the extension studies,
study visits occurred at weeks 69, 86, 104, 121, and 138. If a
patient stopped treatment, then a discontinuation visit was
scheduled.
Efficacy measures
The primary efficacy end points were: the WOMAC pain
subscale (100 mm VAS; 0 = no pain to 100 = extreme pain);
the WOMAC physical function subscale (100 mm VAS; 0 = no
difficulty to 100 = extreme difficult); and the patient’s global
assessment of disease status (100 mm VAS; 0 = ‘‘very well’’ to
100 = ‘‘very poor,’’ assessing the patient’s overall wellbeing).
Safety measures
Patients were monitored for clinical or laboratory AEs by
physical examinations, vital signs, electrocardiograms, and
routine haematology, blood chemistry, and urine analysis at
each study visit. Investigators were instructed to report all AEs
occurring while patients received treatment and for 14 days
after study drug discontinuation. Serious AEs (life-threatening
experiences, those resulting in, or prolonging, hospitalisation,
those causing permanent incapacity, those requiring significant
medical intervention to prevent hospitalisation, incapacity or
death, or a malignancy) were identified by investigators.
Additionally, before initiation of the studies, blinded, external
adjudication committees were organised to evaluate any
potential serious thrombotic CV or upper GI perforations,
ulcers, or bleeding events (PUBs) that occurred during the trial.
Safety was evaluated by various means, including an
examination of patients exceeding predefined limits for
laboratory values of interest (eg, consecutive decreases in
haemoglobin and packed cell volume, increased aminotransfer-
ase values, or increases in serum creatinine), common events
associated with NSAIDs or selective COX-2 inhibitors (eg,
hypertension and lower extremity oedema), and clinical review
of tabulated data.
Power and determination of sample size
Power and sample size were calculated for the efficacy
evaluation during part I of the base study based on the
Table 1 Baseline patient characteristics
Characteristics
Baseline patient characteristics for all enrolled patients
Baseline patient characteristics for patients who








(n = 246) Naproxen (n = 217)
Gender, No (%)
Female 82 (73.2) 322 (72.2) 314 (71.5) 191 (77.6) 156 (71.9)
Male 30 (26.8) 124 (27.8) 125 (28.5) 55 (22.4) 61 (28.1)
Race, No (%)
Asian 1 (0.9) 2 (0.4) 3 (0.7) 1 (0.4) 1 (0.5)
Black 6 (5.4) 18 (4.0) 19 (4.3) 10 (4.1) 5 (2.3)
Multiracial 6 (5.4) 24 (5.4) 20 (4.6) 26 (10.6) 19 (8.8)
Other 10 (8.9) 42 (9.4) 35 (8.0) 31 (12.6) 22 (10.1)
White 89 (79.5) 360 (80.7) 362 (82.5) 178 (72.4) 170 (78.3)
Age (years)
Mean (SD) 63.8 (10.2) 62.59 (9.8) 62.7 (9.7) 62.19 (9.0) 61.51 (9.4)
Range 40 to 87 35 to 92 40 to 87 40 to 84 40 to 87
Body weight (kg)
Mean (SD) 86.4 (18.5) 84.28 (18.9) 85.09 (18.9) 83.90 (18.67) 86.03 (18.44)
Range 51.3 to 138.0 44.8 to 176.9 48.00 to 158.8 47.6 to 176.9 48.0 to 142.9
Primary OA joint, No (%)
Hip 20 (17.9) 100 (22.4) 99 (22.6) 40 (16.3) 38 (17.5)
Knee 92 (82.1) 346 (77.6) 340 (77.4) 206 (83.7) 179 (82.5)
ARA function class, No (%)
I 24 (21.4) 99 (22.2) 90 (20.5) 48 (19.5) 48 (22.1)
II 69 (61.6) 246 (55.2) 269 (61.3) 144 (58.5) 126 (58.1)
III 19 (17.0) 101 (22.6) 80 (18.2) 54 (22.0) 43 (19.8)
ARA, American Rheumatism Association.
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variability seen in a previous etoricoxib dose-ranging study.13
With 200 patients in each active treatment group and 50 in the
placebo group, the detectable differences vs placebo (with 95%
power, a= 0.05, two-tailed) ranged from 12.8 to 14.1 mm for
the primary end points. Prespecified clinical comparability
between etoricoxib 60 mg and naproxen 1000 mg was demon-
strated if the 95% confidence interval (CI) for the mean
differences between the two groups in the time-weighted
average response fell within¡10 mm on a 100 mm VAS for all
three primary end points (primary variables). With this
equivalence range, the sample size of 200 patients for each
treatment group has greater than 95% power to demonstrate
equivalence if the true (not observed) mean difference between
the etoricoxib group and the naproxen group is 0 for all three
primary end points. For all evaluations, lower values were
consistent with improvement. All statistical tests for differences
were two tailed with a = 0.05; p(0.05 was considered
significant.
Statistical analysis
In part I, the primary analysis for each end point was the time-
weighted average response over the 12-week treatment period.
The time-weighted average response is calculated by taking the
time between adjacent observations divided by the time from
the randomisation visit to the last observation in the treatment
period, and using it as the weight for computation of the
average. Analysis of covariance was used to assess time-
weighted average changes from baseline for each efficacy end
point, with treatment and primary study joint as the main
effect and baseline as covariate. Analysis of variance with terms
for treatment and primary study joint was employed for most
end points without relevant baseline measurements. For the
Figure 2 Mean (SE) change from baseline over time in patients continuing to receive the same treatment from baseline to week 121 for the primary end
points: (A) WOMAC pain subscale (100 mm visual analogue scale (VAS)); (B) WOMAC physical function subscale (100 mm VAS); (C) patient and
investigator global assessments of disease status (100 mm VAS).







Patient global assessment of disease status
(VAS*)
Part I (12-week treatment period)
Placebo 215.31 (219.25 to 211.37) 210.27 (214.19 to 26.35) 213.38 (217.51 to 29.26)
Etoricoxib 60 mg 227.94 (230.03 to 225.85) 222.81 (224.89 to 220.74) 226.39 (228.57 to 224.21)
Naproxen 1000 mg 228.57 (230.68 to 226.47) 223.70 (225.78 to 221.61) 226.46 (228.66 to 224.26)
Parts I and II (52-week treatment period; in patients receiving the same treatment for 52 weeks)
Etoricoxib 60 mg 231.03 (233.19 to 228.86) 225.96 (228.24 to 223.69) 227.58 (229.83 to 225.32)
Naproxen 230.60 (232.82 to 228.39) 226.06 (228.39 to 223.73) 227.82 (230.14 to 225.51)
WOMAC, Western Ontario and McMaster Universities OA Index; VAS, visual analogue scale.
*0–100 mm scale.
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patient and investigator global response to therapy end points,
the patient global assessment of disease was used as the
covariate.
In part II and the extensions, the treatment response was
assessed through graphical presentation and tabulation of
mean change from baseline at each study visit. The compar-
ability of etoricoxib and naproxen was examined by the time-
weighed average change from baseline over 52 weeks as
described for part I, and the analysis was limited to patients
who received the same treatment in parts I and II.
For the extensions, efficacy results were assessed over time
within each of the treatment groups by least squares means
changes from baseline obtained from an analysis of covariance
model similar to that used for part I, with appropriate 95% CIs.
No formal hypothesis testing was carried out owing to the non-
randomised, self-selected nature of the patient population in
the extension studies. Only visual examination of the summary
statistics through tables and graphs was performed.
RESULTS
Patient demographics
Of the 997 patients randomised into part I, 838 entered part II
and 463 entered the 86-week extension studies (fig 1). The
baseline characteristics were similar among patients receiving
placebo, etoricoxib, and naproxen; baseline patient character-
istics from part I are representative of the patients in the
extension, and remained similar among the etoricoxib and
naproxen groups (table 1). The most common reasons for
discontinuations in part I were clinical AEs and a lack of
efficacy. In part II, patients discontinued owing to clinical AEs,
lack of efficacy, and withdrawal of consent. Most common
reasons for discontinuation during the 86-week extension were
clinical AEs, withdrawal of consent, and lack of efficacy (fig 1).
Efficacy results
Efficacy over 52 weeks
Etoricoxib 60 mg and naproxen 1000 mg demonstrated sig-
nificantly greater improvements than placebo over the 12-week
treatment period for all efficacy end points. For the three co-
primary efficacy end points, etoricoxib was comparable to
naproxen 1000 mg, as shown by the 95% CIs for the between-
group mean differences, which were contained within the
¡10 mm equivalence bound. The placebo group had a
significantly higher discontinuation rate due to lack of efficacy
than both the etoricoxib (p,0.001) and naproxen 1000 mg
groups (p,0.001) (fig 1). Efficacy responses in the etoricoxib
and naproxen groups were not significantly different.
Furthermore, differences between the active treatments and
placebo were seen at the earliest time point of measurement
(2 weeks after the start of the study drug) and persisted at
about the same magnitude for the 12 weeks. Onset of
treatment effect, as assessed by the WOMAC pain walking on
flat surface and patient global assessment of response to
treatment recorded at 4 hours after the dose, was seen as early
as day 1. Duration of treatment effect after treatment with
etoricoxib or naproxen, as assessed by the WOMAC pain
walking on flat surface and patient global assessment of
response to treatment recorded at 24 hours after the dose, was
significantly different relative to placebo from day 2 onwards.
For patients who continued to receive the same treatment
(etoricoxib or naproxen) during parts I and II of the studies,
treatment effects, as measured by the time-weighted average
change from baseline over the entire 52 weeks of the studies,
were similar between etoricoxib and naproxen 1000 mg.
Efficacy was maintained at a consistent level over the 52 weeks
of the studies for both the etoricoxib and naproxen 1000 mg
treatment groups.
Efficacy over 138 weeks
Graphical examination of the adjusted mean changes from
baseline for the three primary end points (WOMAC pain
subscale, WOMAC physical function subscale, and patient
global assessment of disease) demonstrated a relatively con-
stant treatment effect over the entire 138-week extension
period; results were similar for the etoricoxib and naproxen
groups (fig 2). Clinically important treatment effects from
etoricoxib and naproxen were seen from the first treatment
period at week 2; these treatment effects were significantly
better than those of placebo during part I (table 2; fig 2).
Safety results
All treatments were generally well tolerated in all periods of the
studies. The percentage of patients with any AEs and serious
AEs was similar among all treatment groups. In each study
period, the naproxen group had a numerically greater percen-
tage of patients discontinuing owing to an AE as well as the
greatest percentage of patients with drug-related AEs.
Regardless of treatment group, the most common AEs in the
Table 3 Incidence of clinical adverse experiences (AEs), by study period















Any AE 57 (50.9) 262 (58.7) 279 (63.6) 301 (69.4) 276 (68.3) 179 (72.8) 181 (83.4)
Serious AEs 1 (0.9) 6 (1.3) 9 (2.1) 32 (7.4) 30 (7.4) 26 (10.6) 33 (15.2)
Discontinuations due to AEs 9 (8.0) 24 (5.4) 44 (10.0) 37 (8.5) 46 (11.4) 24 (9.8) 28 (12.9)
Drug related AEs 19 (17.0) 96 (21.5) 128 (29.2) 76 (17.5) 91 (22.5) 42 (17.1) 58 (26.7)
Most common AEs (>5.0% in any treatment group)
Abdominal pain 2 (1.8) 7 (1.6) 22 (5.0) 8 (1.8) 10 (2.5) 2 (0.8) 11 (5.1)
Influenza-like disease 2 (1.8) 13 (2.9) 13 (3.0) 27 (6.2) 13 (3.2) 5 (2.0) 11 (5.1)
Upper respiratory infection 6 (5.4) 34 (7.6) 35 (8.0) 47 (10.8) 43 (10.6) 33 (13.4) 18 (8.3)
Hypertension 7 (6.3) 23 (5.2) 13 (3.0) 32 (7.4) 17 (4.2) 27 (11.0) 23 (10.6)
Dyspepsia 2 (1.8) 9 (2.0) 22 (5.0) 11 (2.5) 11 (2.7) 6 (2.4) 5 (2.3)
Epigastric discomfort 3 (2.7) 13 (2.9) 24 (5.5) 13 (3.0) 17 (4.2) 6 (2.4) 9 (4.1)
Heartburn 4 (3.6) 12 (2.7) 23 (5.2) 10 (2.3) 10 (2.5) 4 (1.6) 4 (1.8)
Nausea 4 (3.6) 14 (3.1) 23 (5.2) 8 (1.8) 4 (1.0) 3 (1.2) 4 (1.8)
Sinusitis 2 (1.8) 9 (2.0) 7 (1.6) 8 (1.8) 15 (3.7) 13 (5.3) 12 (5.5)
Back pain 6 (5.4) 3 (0.7) 6 (1.4) 21 (4.8) 12 (3.0) 15 (6.1) 13 (6.0)
Bronchitis 1 (0.9) 9 (2.0) 6 (1.4) 14 (3.2) 12 (3.0) 11 (4.5) 12 (5.5)
Urinary tract infection 0 (0.0) 14 (3.1) 11 (2.5) 21 (4.8) 20 (5.0) 13 (5.3) 18 (8.3)
Results are shown as No (%).
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three study periods overall were upper respiratory infection and
hypertension (table 3).
Hypertension occurred in 6.3% (placebo), 5.2% (etoricoxib),
and 3.0% (naproxen) of patients during the placebo-controlled
part I; 7.4% (etoricoxib) and 4.2% (naproxen) during part II of
the base period; and 11% (etoricoxib) and 10.6% (naproxen)
during the 86-week extension period. The observed increase in
incidence over time in all treatment groups is not unexpected as
these results represent a cumulative incidence of AEs over time.
Other renovascular AEs such as lower extremity oedema and
congestive heart failure occurred at a lower incidence than that
found with hypertension AEs and with similar incidence
among the treatment groups in all three treatment periods.
Discontinuations owing to renovascular AEs were rare in all
treatment groups (table 4).
In part I, the incidence of GI nuisance AEs (ie, abdominal
pain, acid reflux, dyspepsia, epigastric discomfort, heartburn,
nausea and vomiting) was similar for etoricoxib and placebo;
GI nuisance AEs were more common in the naproxen group. In
part II, the etoricoxib and naproxen groups had a similar
proportion of patients with GI nuisance AEs, whereas they
occurred with greater frequency in the naproxen group
compared with the etoricoxib group during the extension
period (table 4).
Upper GI PUB events (confirmed by an external adjudication
committee) did not occur in patients receiving etoricoxib during
part I of the base period, while 7 (1.6%) patients receiving
naproxen experienced a GI PUB. In part II of the base period, 5
(1.2%) patients receiving etoricoxib and 11 (2.7%) patients
receiving naproxen experienced a GI PUB event. GI PUB events
occurred in 2 (0.8%) patients in the etoricoxib group and 13
(5.9%) patients in the naproxen group during the 86-week
extension period. The following specific PUB events occurred in
the etoricoxib group: duodenal ulcer and upper GI haemor-
rhage. In the naproxen group, duodenal ulcers, gastric ulcers,
and upper GI haemorrhages occurred.
During part I, 1 (0.2%) patient in the etoricoxib group had a
confirmed serious CV AE compared with none in the naproxen
group. In part II, 10 (2.3%) etoricoxib patients had thrombotic
CV events compared with 2 (0.5%) naproxen patients.
Confirmed thrombotic CV events occurred in 2 (0.8%)
etoricoxib patients and 4 (1.8%) naproxen patients in the 86-
week extension period. These thrombotic CV events included
acute myocardial infarction and ischaemic stroke in the
etoricoxib group, and, in the naproxen group, acute myocardial
infarction, transient ischaemic attack, and a pulmonary
embolism. All patients with confirmed thrombotic CV events
recovered.
DISCUSSION
The present report provides data from a combined analysis of
two, long-term studies of identical design comparing the
efficacy and safety of etoricoxib 60 mg and naproxen
1000 mg in patients with OA. The 12-week, placebo-controlled
period of the international study from the present analysis was
previously reported. The efficacy of etoricoxib was better than
that of placebo and similar to that of naproxen; both etoricoxib
and naproxen were also generally well tolerated.14 The base
period of the American study demonstrated similar results.15 In
the present, combined analysis of both studies, the efficacy of
etoricoxib and naproxen was comparable; clinical improve-
ments, as assessed by the primary efficacy end points, were
observed by the first treatment visit, 2 weeks after randomisa-
tion, and maintained for up to 138 weeks. Both treatments
were generally well tolerated. Although a similar proportion of
patients in each treatment group experienced an AE over the
entire course of these studies, the specific types of AE that
occurred in each treatment group differed to some degree.
Hyptertension is a common comorbidity in patients with OA
and is also a condition that may be associated with the use of
both selective and traditional NSAIDs owing to their effects on
renal prostaglandins.16 17 In a pooled analysis of studies in the
etoricoxib development programme, etoricoxib demonstrated a
shallow dose response with a generally similar incidence of
hypertension to that of traditional NSAIDs. In comparisons
with ibuprofen, the incidence was slightly lower with etor-
icoxib, whereas in comparisons with naproxen the incidence
was slightly higher with etoricoxib; none of these differences
were interpreted as clinically meaningful.12 In a large, rando-
mised, controlled trial in patients with OA comparing etoricoxib
90 mg (1.5 times the recommended OA dose) versus the
traditional NSAID, diclofenac 150 mg, etoricoxib 90 mg
demonstrated a significantly higher incidence of hyperten-
sion.18 In the current studies, hypertension was among the most
common AE to occur for both etoricoxib and naproxen. The
incidence of hypertension was numerically greater with
etoricoxib than with naproxen, which is consistent with the
results of previous analyses.12 The medical significance of these
Table 4 AEs of special interest
Special interest AEs
















GI nuisance AEs 14 (12.5) 50 (11.2) 102 (23.2) 54 (12.4) 51 (12.6) 19 (7.7) 31 (14.3)
Discontinuations 2 (1.8) 5 (1.1) 18 (4.1) 6 (1.4) 8 (2.0) 0 (0.0) 3 (1.4)
Renovascular AEs
Hypertension 7 (6.3) 23 (5.2) 13 (3.0) 32 (7.4) 17 (4.2) 27 (11.0) 23 (10.6)
Discontinuations 0 (0.0) 1 (0.2) 1 (0.2) 1 (0.2) 0 (0.0) 1 (0.4) 0 (0.0)
Lower extremity oedema 2 (1.8) 10 (2.2) 9 (2.1) 10 (2.3) 13 (3.2) 8 (3.3) 7 (3.2)
Discontinuations 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 1 (0.4) 0 (0.0)
Congestive heart failure 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 2 (0.5) 0 (0.0) 2 (0.9)
Discontinuations 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Confirmed serious thrombotic CV AEs and upper GI bleeding AEs
Confirmed serious thrombotic CV
AEs 0 (0.0) 1 (0.2) 0 (0.0) 10 (2.3) 2 (0.5) 2 (0.8) 4 (1.8)
Confirmed upper GI bleeding
AEs 0 (0.0) 0 (0.0) 7 (1.6) 5 (1.2) 11 (2.7) 2 (0.8) 13 (5.9)
Results are shown as No (%).
AEs, adverse experiences; GI, gastrointestinal; CV, cardiovascular.
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observations is probably limited, however, as discontinuations
from hypertension were infrequent and generally similar
among both groups. Furthermore, the occurrence of other
renovascular AEs, such as lower extremity oedema and
congestive heart failure, were generally similar among patients
who received etoricoxib and naproxen throughout the 138-
week treatment period. These data demonstrate the importance
of monitoring the blood pressure of all patients who are treated
with any NSAID, including etoricoxib.
Previous studies have suggested that etoricoxib is associated
with a lower frequency of gastrointestinal AEs than patients
receiving chronic treatment with traditional, non-selective
NSAIDs.19 20 The present analysis supports the outcomes from
these previous studies; patients receiving etoricoxib experi-
enced GI AEs with a reduced incidence in comparison with
patients receiving naproxen during part I of the study. Owing to
the self-selected nature of the study group beyond part I of the
study, the lack of a demonstrable difference in GI tolerability
among the treatment groups was not unexpected. However,
there was an observable difference in GI tolerability during the
extension period in favour of etoricoxib, although the extension
data should be viewed with caution because they also are not
representative of a randomised patient group. Additionally, the
proportion of patients with GI perforations, ulcers, or bleeding
was smaller in the etoricoxib group than in the naproxen group.
Although these studies were not powered specifically to
examine CV risk, this report presents the available data
obtained from them. In the current studies, the incidence of
thrombotic CV events was low in each treatment group, with a
greater proportion of patients experiencing a thrombotic CV
event in the etoricoxib group than in the naproxen group. These
results are consistent with a previous analysis of CV data from
the etoricoxib development programme, in which confirmed
thrombotic CV events occurred at a similar rate among patients
treated with etoricoxib and traditional NSAIDs, with the
exception of naproxen. In comparisons with naproxen, the rate
of confirmed thrombotic CV events was higher for etoricoxib.21
These results are also consistent with CV safety data observed
in randomised trials of other COX-2 selective inhibitors, in
which a lower incidence of thrombotic CV events was observed
with naproxen.7 22 23
CONCLUSIONS
In summary, etoricoxib 60 mg and naproxen 1000 mg had similar
efficacy for the treatment of OA, which was maintained over
138 weeks. Both agents were generally well tolerated. Although
these studies were not powered to evaluate the relative risk of GI
or CV events, the safety data from these studies suggest that
etoricoxib has a more favourable GI safety and tolerability profile
than naproxen, whereas naproxen is associated with a numeri-
cally lower incidence of thrombotic CV events.
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